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1 |  INTRODUCTION
Glucose is the essential metabolic fuel for brain. Glucose 
transport across the blood-brain barrier (BBB) and astro-
cyte plasma membrane is exclusively facilitated by the 
glucose transporter type 1 (Glut1). Glut1 is primarily ex-
pressed in endothelial cells forming the BBB and in as-
trocytes, whereas Glut3 is primarily expressed in neurons. 
Consequently, a Glut1 genetic defect would impair glucose 
transport across the BBB and into astrocytes, resulting in 
a cerebral “energy crisis” termed glucose transporter type 
1 deficiency syndrome (Glut1DS) (for comprehensive 
review see1). Patients classically present with infantile-on-
set epilepsy, deceleration of head growth, impaired neuro-
logical growth and development, and complex movement 
disorders. Symptoms develop in an age-specific pattern: 
Paroxysmal eye-head movements and seizures are early 
presenting features in infancy. Developmental impairment 
becomes increasingly apparent and is followed by ataxia, 
paroxysmal exertion-induced dystonia, and further move-
ment abnormalities that develop over time often becom-
ing the major symptoms in adolescents and adult Glut1DS 
patients. The principal diagnostic tool is a lumbar puncture 
showing low CSF glucose and low to low-normal lactate 
Abstract
Glut1 deficiency syndrome (Glut1DS) is a brain energy failure syndrome caused by 
impaired glucose transport across brain tissue barriers. Glucose diffusion across tis-
sue barriers is facilitated by a family of proteins including glucose transporter type 1 
(Glut1). Patients are treated effectively with ketogenic diet therapies (KDT) that pro-
vide a supplemental fuel, namely ketone bodies, for brain energy metabolism. The in-
creasing complexity of Glut1DS, since its original description in 1991, now demands 
an international consensus statement regarding diagnosis and treatment. International 
experts (n = 23) developed a consensus statement utilizing their collective profes-
sional experience, responses to a standardized questionnaire, and serial discussions 
of wide-ranging issues related to Glut1DS. Key clinical features signaling the onset 
of Glut1DS are eye-head movement abnormalities, seizures, neurodevelopmental im-
pairment, deceleration of head growth, and movement disorders. Diagnosis is con-
firmed by the presence of these clinical signs, hypoglycorrhachia documented by 
lumbar puncture, and genetic analysis showing pathogenic SLC2A1 variants. KDT 
represent standard choices with Glut1DS-specific recommendations regarding dura-
tion, composition, and management. Ongoing research has identified future inter-
ventions to restore Glut1 protein content and function. Clinical manifestations are 
influenced by patient age, genetic complexity, and novel therapeutic interventions. 
All clinical phenotypes will benefit from a better understanding of Glut1DS natu-
ral history throughout the life cycle and from improved guidelines facilitating early 
diagnosis and prompt treatment. Often, the presenting seizures are treated initially 
with antiseizure drugs before the cause of the epilepsy is ascertained and appropriate 
KDT are initiated. Initial drug treatment fails to treat the underlying metabolic distur-
bance during early brain development, contributing to the long-term disease burden. 
Impaired development of the brain microvasculature is one such complication of de-
layed Glut1DS treatment in the postnatal period. This international consensus state-
ment should facilitate prompt diagnosis and guide best standard of care for Glut1DS 
throughout the life cycle.
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concentrations in the setting of normal blood glucose and 
lactate concentrations. Most patients have autosomal dom-
inant de novo heterozygous mutations in SLC2A1 as the 
cause of the Glut1DS. Ketogenic diet therapies (KDT) pro-
vide a supplemental metabolic fuel for the brain and usu-
ally control seizures effectively. The beneficial effects on 
developmental delay and movement abnormalities, unfor-
tunately, appear to be less striking.
Since the initial description of Glut1DS in 1991,2 the num-
ber of affected individuals has steadily grown facilitated by the 
advent of molecular diagnosis. A recently published prospec-
tive Scottish population-based study reported a birth incidence 
of 1:24 000 presenting with epilepsy in the first three years.3 In 
line with a recent predicted incidence of 1.65-2.22 per 100 000 
births,4 this is likely a minimum incidence as cases may pres-
ent later with epilepsy or movement disorders. In retrospec-
tive studies, the prevalence of Glut1DS was estimated to be 
1:83 000 in Denmark5 and 1:90 000 in Australia,6 respectively. 
The estimated point prevalence of Glut1DS in Norway was 2.6/
million inhabitants.7 All age groups from infants to adults are 
affected and present with age-specific symptoms. Novel diag-
nostic tools and research strategies are emerging.
Recently, an international consensus on the optimal clin-
ical management of children receiving dietary therapies for 
epilepsy was updated and serves as an excellent general 
guideline for KDT.8 Some issues relevant to Glut1DS were 
addressed in this publication. However, it has become clear 
that an international expert consensus focusing specifically 
on Glut1DS was required. This article highlights current 
Glut1DS knowledge and provides the first international con-
sensus statement regarding the current standard of care for 
this condition.
2 |  METHODS
For the consensus guideline, the project lead authors, JK, 
EK, and DCD, identified other international experts for 
Glut1DS who have published on this entity either as first or 
senior authors in peer-reviewed journals or have had exten-
sive experience as dieticians (EN, BL) in the management 
of Glut1DS patients. A maximum of two authors per medi-
cal center was allowed resulting in 21 physicians and two 
dietitians from 10 nations (Europe: twelve, USA: eight, 
Argentina: one, Australia: one, and Japan: one). Each par-
ticipant was asked to prepare a brief overview of the cur-
rent state of the art for a specific Glut1DS topic. This expert 
opinion was then circulated to all authors for comments and 
revisions, surveys were circulated regarding controversial 
issues, and face-to-face consensus meetings were held dur-
ing the 2nd European Glut1DS conference in East Grinstead, 
UK, on June 22, 2018, and the 8th biannual Glut1 Deficiency 
Foundation Conference on July 11, 2019, and July 12, 2019 
in Washington DC, USA Authors were instructed to cite 
peer-reviewed publications when available. In the absence 
of published literature, the participants were asked to base 
recommendations on their personal professional or collective 
medical center experience. Sections were collected, incor-
porated into a full document, and then emailed to the entire 
group for further review. For the surveys, 10 questions with 
50 subheadings were emailed to 13 experts (one author per 
center) (see Data S1). Survey results were discussed at the 
2nd European Glut1DS meeting. Additional international 
experts for specific Glut1DS-associated topics were sought 
resulting in a total of 23 experts. Survey results were incor-
porated into the manuscript, providing percentage responses 
for individual topics. This process allowed for the sharing of 
expertise when the recommendation was controversial, and 
consensus was difficult to achieve. All participants reviewed 
and approved the final manuscript prior to submission.
3 |  STATE OF THE ART IN 
GLUT1DS AND CONSENSUS 
RECOMMENDATIONS
3.1 | Clinical features in Glut1DS
Epilepsy: Pharmaco-resistant seizures are frequently 
the first sign of Glut1DS. Any type of seizure can be ob-
served.9 Generalized seizures are more frequent than focal 
seizures.10,11 Early-onset absence epilepsy (onset prior to 
age 4  years)12,13 and epilepsy with myoclonic-atonic sei-
zures (Doose syndrome) have been associated with SLC2A1 
pathogenic variants. Any epilepsy associated with movement 
disorders should suggest Glut1DS. In contrast, catastrophic 
epilepsy syndromes such as Lennox-Gastaut syndrome have 
Key Points
• Early Glut1DS diagnosis is confirmed by char-
acteristic clinical features, low CSF glucose, and 
pathogenic SLC2A1 variants.
• Clinical features and treatment responses change 
with advancing patient age. Best outcomes corre-
late with early treatment.
• Age-specific ketogenic diet therapies remain the 
standard of care.
• Continuing challenges are continuity of care dur-
ing transition to adulthood, paroxysmal dyskine-
sias, intolerance to ketogenic diet therapies, and 
potential long-term complications.
• Future therapies will focus on small molecule res-
toration of Glut1 protein/function, supplemental 
metabolic augmentation, and SLC2A1 transfer 
strategies.
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not been reported. The initiation of KDT is highly effective 
in controlling seizures. Dietary treatment can achieve seizure 
freedom within a couple of days with normalization of EEG 
changes, frequently allowing for the withdrawal of any an-
tiseizure medicines that might have been started before the 
correct diagnosis of Glut1DS had been established. Epilepsy 
tends to be the major clinical problem in infants and young 
children with Glut1DS, whereas seizures tend to decline or 
disappear in later childhood, adolescence, and adulthood.
Movement Disorders: In early infancy, distinctive par-
oxysmal eye-head movements are the second most common 
initial sign of Glut1DS, after seizures.14–16 Episodes are typi-
cally involuntary and brief. The eye movements are repeated, 
multidirectional, saccadic, usually conjugate, and often ac-
companied by a head movement in the same direction. Later 
in childhood, other paroxysmal events emerge but the se-
verity is highly variable. Presentation often involves some 
type of motor disturbance such as involuntary movements, 
ataxia, or weakness/paralysis. Awareness is generally pre-
served. Gradual clinical improvement, decreased frequency, 
and decreased severity of paroxysmal events are typical in 
adult life.17–30 Paroxysmal nonmotor episodes include mi-
graines, behavioral disturbances, cyclical vomiting, and sleep 
episodes.19,22,24,30
In general, movement disorders are characteristic of 
Glut1DS. Severity ranges from minimal to severe. The move-
ments can be persistent or paroxysmal, classically present 
preprandially, and are mitigated by meals. Persistent move-
ment disorders include spasticity, ataxia, and dystonia often 
producing disturbances of gait, followed by chorea and 
tremor.19,24,25 Ataxia is increasingly evident in late infancy 
as the child stands and starts to walk.25 Ataxia is more trun-
cal than appendicular. Chorea is often mild and involves 
the face and the distal upper limbs. A terminal intention 
tremor is frequent and often associated with other signs of 
cerebellar dysfunction. Myoclonus is generally epileptic; 
nonepileptic myoclonus is less common and includes startle 
myoclonus, action, and postural myoclonus.17,19,27 Dyspraxia 
is under-recognized and includes oculomotor dyspraxia and 
oro-buccal dyspraxia.19,28 Paroxysmal movement disorders 
affect approximately 75% of patients and include paroxysmal 
eye-head movements, paroxysmal exercise-induced dyski-
nesia (PED), paroxysmal events manifested by major motor 
dysfunction, and paroxysmal events with complex neuro-
logical symptoms.31 These movement abnormalities are fre-
quent and often precipitated by fasting and exercise.18–21,26,27 
Potential triggers are emotional stress, fever, fatigue, insuf-
ficient ketosis, sleep deprivation, temperature changes, and 
drugs.17–22,26–29
Microcephaly may be acquired during infancy and is of 
varying degree likely correlating with clinical severity. 32
Development and cognitive function: Glut1DS is asso-
ciated with mild-to-severe intellectual disability, with the 
degree of severity being proportional to the overall dis-
ease severity.20,26,28,33 Dysarthria, with varying degrees of 
speech impairment, is observed in all affected individuals. 
Social adaptive behavior is an exceptional strength.23,25 
Performance skills usually are more affected than verbal 
skills, with prominent deficiencies in visuospatial and vi-
suomotor abilities. Timing of KDT introduction is a pre-
dictive factor for cognitive outcome.29,34 Early dietary 
treatment correlates with better intellectual and social 
adaptive skills.25
Atypical manifestations: Rare features described in 
Glut1DS include writer's cramp, intermittent ataxia, total 
body paralysis, Parkinsonism, and nocturnal painful muscle 
cramps in the legs.32 Alternating hemiplegia of childhood, 
hemiplegic migraine, cyclic vomiting, and stroke-like ep-
isodes with paroxysmal hemiparesis, dysarthria, or apha-
sia have been described in individual patients.23,35,36 Other 
rare features include hemolytic anemia associated with 
PED, hepatosplenomegaly, periventricular calcifications, 
brain atrophy, pseudohyperkalemia, cataracts, and retinal 
dysfunction.18,37
Adult Glut1DS: Data on adult Glut1DS are just emerg-
ing. Long-term prognosis and long-term adverse effects 
of KDT largely remain unknown. Changes in symptom-
atology over time include a shift from infantile-child-
hood onset epilepsy to adolescent-adult onset movement 
disorders including PED.24,25,31 Evaluation and treatment 
of adult Glut1DS also differ from pediatric Glut1DS. An 
extended metabolic evaluation may not be necessary, and 
for women of childbearing age, a pregnancy test should be 
considered prior to a KDT given that the risks of teratoge-
nicity are unknown. Initiation of a KDT in adults is con-
troversial given the side effects described in drug-resistant 
childhood epilepsy including osteopenia, osteoporosis,38 
potential cardiovascular risks,39,40 and unclear effects on 
pregnancy. Also, energy and nutritional requirements in 
the mature brain are less than in the developing brain. In 
general, the modified Atkins diet (MAD) is considered a 
reasonable alternative for adolescents and adults41,42 when 
treating poorly controlled seizures and paroxysmal move-
ment disorders.
Committee conclusions
The Glut1DS phenotype becomes protean with advancing 
age. Clinical features consistent with Glut1DS include the 
following
• Any unexplained movement disorder with spasticity, dys-
tonia, and ataxia,
• Complete seizure control by KDT in children with drug-re-
sistant epilepsy,
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• Unexplained paroxysmal events at any age,
• Early-onset absence epilepsy (under 4 years of age), and
• Myoclonic-atonic epilepsy (Doose syndrome).
Experts rated the importance of clinical features for the 
diagnosis of Glut1DS as (a) an isolated clinical sign or (b) 
in combination with other neurological signs (survey ques-
tion 2): Paroxysmal eye-head movements in infancy were 
felt to be specific for Glut1DS (12 of 13 centers; 92%). 
In contrast, developmental delay otherwise unexplained, 
alternating hemiplegia, nonspecific paroxysmal events, 
and stroke-like episodes were felt to be clinical features 
that rarely occurred as isolated clinical signs in this entity 
(Table 1).
3.2 | Diagnosis of Glut1DS
EEG: In Glut1DS of all ages, an interictal EEG is often nor-
mal. Abnormalities appear more common at certain ages: In 
infants, focal slowing and epileptiform discharges are more 
prevalent, whereas in children ages two years or older 2.5- 
to 4-Hz generalized spike-wave pattern is observed.43 An 
intriguing feature, when present, is preprandial EEG abnor-
mality that improves with feeding as glucose is restored to a 
starving brain.44
Lumbar puncture: Low CSF glucose values in the set-
ting of normoglycemia, termed hypoglycorrhachia, repre-
sent the metabolic hallmark of Glut1DS.45 Other causes 
of hypoglycorrhachia such as hypoglycemia, meningitis, 
subarachnoid hemorrhage, or ventriculoperitoneal shunt 
systems need to be excluded.46–48 In Glut1DS, CSF lac-
tate levels are always low-normal or abnormally low, 
separating this condition from other diseases causing im-
paired brain energy metabolism, most notably mitochon-
drial diseases. The lumbar puncture should be performed 
in a postabsorptive state following a four- to six-hour fast. 
Blood glucose measurements should be determined imme-
diately prior to performing the lumbar puncture to avoid 
stress-related hyperglycemia. Reference ranges are gen-
der-independent, but age-specific.49 Hypoglycorrhachia in 
typical Glut1DS was originally defined as a cutoff value 
of 2.2 mmol/L (40 mg/dL).2,46 In a retrospective analysis 
of 147 patients, CSF glucose levels ranged from 0.9 to 
2.8 mmol/L (16.2 to 50.5 mg/dL) and CSF to blood glucose 
ratios ranged from 0.19 to 0.59.45 It is now clear that milder 
phenotypes may have CSF values of 2.2 to 2.9 mmol/L (41-
52 mg/dL), but never normal.46
Neuroimaging: Cranial magnetic resonance imaging 
(MRI) is useful to exclude structural and neurometabolic ep-
ileptic encephalopathies. One of four patients has abnormal 
nonspecific cranial MRI findings: hyperintensity of subcor-
tical U-fibers, prominence of perivascular Virchow spaces, 
and delayed myelination for age.32,50,51 18F-deoxyglucose-
positron emission tomography (18F-FDG-PET) can be a 
useful additional diagnostic tool. A diminished FDG signal 
emanating from the cerebellum, thalamus, and cerebral cor-
tex, and an apparent increase in glucose accumulation in the 
striatum, particularly in the caudate nucleus, is the imaging 
signature of Glut1DS. The thalami display hypometabolism 
comparable to the degree of cortical depression. Within the 
cerebral cortex, a more pronounced uptake deficit is observed 
in the mesial temporal lobe.29,52,53 Magnetic resonance spec-
troscopy imaging has been applied in single cases of Glut1DS 
for diagnostic evaluation of brain energy metabolism but con-
trolled studies are needed to assess diagnostic sensitivity and 
specificity.54,55
Genetic analysis: Sequence analysis identifies heterozy-
gous de pathogenic variants (or rarely, biallelic pathogenic 
variants) in SLC2A1 in 81%-89% of patients.32 Another 
11%-14% of patients are confirmed by deletion/duplication 
analysis.32 However, the absence of SLC2A1 pathogenic 
T A B L E  1  Ranking of clinical features specific for Glut1DS (question 2)
Clinical feature specific for Glut1DS that warrants lumbar puncture and SLC2A1 analysis Isolated In combination
Paroxysmal eye-head movements in infancy 12/13 (92%) 0/13 (0%)
Early-onset absence epilepsy <4 y of age 10/13 (77%) 3/13 (23%)
Any complex movement disorder with spasticity, dystonia, ataxia as predominant features 6/13 (46%) 7/13 (54%)
Effective seizure control by KDT in children with drug-resistant epilepsy 6/13 (46%) 7/13 (54%)
Myotonic-atonic epilepsy (Doose syndrome) 6/13 (46%) 6/13 (46%)
Unexplained paroxysmal events (any age) 5/13 (38%) 8/13 (62%)
Early-onset drug-resistant childhood epilepsy unresponsive to antiseizure medication 4/13 (31%) 9/13 (69%)
Alternating hemiplegia 2/13 (15%) 10/13 (77%)
Stroke-like episodes 2/13 (9%) 9/13 (69%)
Developmental delay otherwise unexplained 0/13 ( 0%) 12/13 (92%)
The potential to support the diagnosis of Glut1DS as either an isolated or combined clinical sign is shown as percentage of total (13 centers). Total numbers do not 
always add up to n = 13 as some questions were not answered by all centers.
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variants does not always exclude Glut1DS. Pathogenic 
mechanisms may involve noncoding RNA genes as well 
as downstream defects in Glut1 translation, transcription, 
processing, activating, and trafficking (see Research sec-
tion). SLC2A1-negative patients can be diagnosed on the 
basis of hypoglycorrhachia and distinctive clinical features 
(Table 2), especially when responding favorably to KDT. 
Several specific de novo pathogenic SLC2A1 variants af-
fecting functional domains of the glut1 transporter have 
been identified. Also, pathogenic variants causing familial 
autosomal dominant and autosomal recessive inheritance 
have been reported in individual families.56–58 The type of 
genetic mutation often correlates with phenotypic severity: 
missense variants (mild and moderate severity); splice site 
and nonsense variants and insertions, deletions, and exon 
deletions (moderate and severe severity); and complete 
gene microdeletions (severe severity).
Laboratory studies: In the absence of pathogenic SLC2A1 
variants, an impaired 3-O-methyl-D-glucose uptake in eryth-
rocytes between 35% and 74% of controls is diagnostic (for 
details see32). Western blot and oocyte expression analysis 
are additional tools to confirm pathogenicity. Recently, the 
measure of Glut1 present on the surface of the circulating red 
blood cells, as determined by flow cytometry (METAglut1TM 
test), has been reported to be of diagnostic value for 
Glut1DS.59
Committee conclusions
Recommendations for Glut1DS diagnosis generated from 
the survey (13 centers, question 1) and expert discussions are 
shown in Table 2. All authors agreed that the definite diagno-
sis of Glut1DS requires the presence of characteristic clini-
cal features, hypoglycorrhachia, and a pathogenic variant in 
SLC2A1 (13/13, 100%). Controversies arose when some of 
these diagnostic criteria were negative or of unclear signifi-
cance (survey question 1). In the presence of characteristic 
clinical features, most experts felt that two of three criteria 
were sufficient for the diagnosis. If the patient is asympto-
matic, the clinical diagnosis is only justified, in the setting 
of hypoglycorrhachia and pathogenic SLC2A1 variant, if the 
patient is a presymptomatic member in a familial Glut1DS 
setting.
Hypoglycorrhachia, epilepsy, movement disorders, 
and paroxysmal neurologic dysfunction may have other 
causes.32 Most centers perform brain MRI (10/13, 77%, 
and EEG/fasting EEG (8/13, 62%) to identify structural or 
epileptic encephalopathies. Opinions were mixed regard-
ing metabolic parameters that should be measured (survey 
question 3): Blood lactate for mitochondrial disorders was 
determined in half the centers (7/13 54%), and basic blood 
parameters for renal, liver, and thyroid function and amino/
organic acid analysis for metabolic disease were determined 
by just one-third of centers (5/13, 38%). Brain PET (1/13, 
8%) and fasting lipid analyses (0/13, 0%) were not consid-
ered standard investigations for the diagnosis of Glut1DS 
but were obtained in single centers. Glucose uptake studies 
by isolated erythrocytes also confirm the diagnosis but are 
not available on a commercial basis. The diagnostic value 
of the METAglut1TM test is not yet established as a standard 
diagnostic tool for Glut1DS.
3.3 | Treatment of Glut1DS
Ketogenic Diets: In Glut1DS, dietary therapy should be ini-
tiated as early as possible, providing the developing brain 
with a supplemental supply of metabolic fuel. Seizure con-
trol when managed with a classical KDT or MAD is good—
one survey of Glut1DS families described 80% of patients 
with >90% seizure reduction including 64% of patients who 
no longer required antiseizure drugs.60 Ineffective seizure 
control in Glut1DS despite KDT has been reported.29,61 
Movement disorders and cognitive issues also improve with 
dietary KDT.25,29,34,47 The general management of KDT for 
T A B L E  2  Consensus recommendation for Glut1DS diagnosis 
generated from survey results and discussions based on three 
key diagnostic criteria: characteristic clinical features, definite 
hypoglycorrhachia, and pathogenic <em>SLC2A1</em> variants




0 negative not required 
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drug-resistant childhood epilepsy and for Glut1DS is de-
scribed in the revised international consensus.8 Specific as-
pects for KDT in Glut1DS are shown in Table 3. All patients 
with Glut1DS should monitor their ketosis by determination 
of beta-hydroxybutyrate in capillary or venous blood. Urine 
ketones are a qualitative measure of acetoacetate and as such 
are not as adequate to quantitatively monitor ketonemia in 
Glut1DS patients.32,47 Classic KDT typically provide higher 
levels of ketosis and may be preferred in younger children, 
especially those under age three years.62,63 In adolescents 
and adults, the MAD may be more feasible for quality of life 
and compliance.64 The low glycemic index treatment (LGIT) 
provides very low ketones, has no evidence of benefit for 
Glut1DS, and is not recommended.47,65 More effective KDT 
should be used in Glut1DS. If KDT are intolerable, increas-
ing carbohydrates in regular diets has been described as an 
option.66,67 Carnitine levels need to be monitored as patients 
may become secondarily carnitine-deficient over time.68 
Although most children with epilepsy on KDT can be tran-
sitioned off this treatment after two years, this plan is not 
appropriate for a child with Glut1DS. The benefits of KDT 
have no clear “end-date” and are thought to extend into adult-
hood. 69
Concurrent antiseizure drugs: Treating Glut1DS with 
antiseizure medications does not address the underlying 
metabolic defect. As a result, no individual drug can be rec-
ommended. In addition to being therapeutically ineffective, 
medications may do harm. Several examples were discussed. 
For example, carbonic anhydrase inhibitors such as acetazol-
amide, topiramate, and sulthiame may aggravate acidosis.70 
Topiramate, acetazolamide, and zonisamide may increase the 
risk of urolithiasis, especially in combination with KDT.71 
Decreased efficacy of KDT has been reported with the 
concomitant use of lamotrigine in childhood drug-resistant 
epilepsy.72 Barbiturates, diazepam, sodium valproate, chlo-
ralhydrate, methylxanthine, and ethanol are nonspecific in-
hibitors of Glut1 function in vitro. No inhibitory effects in 
vitro were observed for carbamazepine and phenytoin.73–76 
Prolonged exposure to phenytoin and its metabolite 5-(4-hy-
droxyphenyl)-5-phenylhydantoin was shown to stimulate 
glucose transport in vitro by up to 30%-60%.76 However, the 
implication of these in vitro data for the clinical setting re-
mains unclear.
Ketone salts and ketoesters: Ketone salts and ketoesters 
may serve as a supplemental fuel for the brain without di-
etary restriction. Both compounds can be administered 
orally and can achieve ketone plasma levels equivalent to 
KDT.77 Sodium 3-hydroxybutyrate has been used individ-
ually in metabolic diseases such as multiple acyl-CoA-de-
hydrogenase deficiency and specific glycogen storage 
diseases.78 Oral ketone salts are freely available, but daily 
volumes up to 400 grams taste unpleasant and may cause so-
dium overload. Triheptanoin provides 5-carbon ketone body 
ketosis and an additional anaplerotic effect.79,80 Despite 
promising initial reports,55,81 a phase 3 study of trihepta-
noin (UX007) for the treatment of Glut1DS (ClinicalTrials.
gov Identifier: NCT01993186) failed to meet its primary 
and secondary endpoints. A similar phase 3, randomized, 
double-blind, placebo-controlled, crossover study to as-
sess the efficacy and safety of triheptanoin (UX007) in the 
treatment of movement disorders associated with Glut1DS 
(ClinicalTrials.gov Identifier: NCT02960217) was halted 
prematurely due to lack of efficacy (https://clini caltr ials.
gov/ct2/show/ NCT02960217). Peer-reviewed National 
Institutes of Health funded studies using standard clinical 
trial criteria also are currently underway (NCT03041363, 
Criteria
KDT for drug-resistant childhood 
epilepsy
KDT for Glut1 
Deficiency Syndrome
Indication:
Epilepsy Insufficient seizure control by ≥two 
anticonvulsive medications
1st line treatment
Movement disorder --- 1st line treatment
Development --- 1st line treatment
Treatment
Initiation Optional At diagnosis, any age, 
as early as possible
Duration 2 y + Into adolescence/
adulthood
Ketosis and KDT ratio Variable As high as tolerated
LGIT Optional Not recommended
Monitoring ketosis Urine and blood ketones Blood ketones
Carnitine levels Optional Recommended
Monitoring side effects (+) (+++)
T A B L E  3  Comparison of indication 
and treatment recommendations for KDT 
in drug-resistant childhood epilepsy and 
Glut1DS
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NCT03181399, NCT03301532). Novel approaches are on-
going, targeting small molecules and other biologics to en-
hance Glut1 expression and function.82 Anecdotal reports 
have described individual benefits of acetazolamide and 
L-DOPA as treatment for paroxysmal movement disorders 
in Glut1DS.83–85
Committee conclusions
Ketogenic diet therapies remain the treatment of choice for 
Glut1DS and should be started as early as possible (13/13, 
100%, survey questions 4,5,8). In children under age two 
years, a classical 3:1 KDT is the treatment of choice. Most 
centers continue a classical KDT to obtain a high degree of 
ketosis to meet the energy demands of the developing brain. 
Most centers also believe that for adolescents, adults, and 
noncompliant patients, the MAD provides a good alterna-
tive to the classical KDT (12/13, 92%). LGIT is not recom-
mended as treatment for Glut1DS (12/13, 92%). All centers 
recommend continuing the KDT for as long as tolerated 
by the patient. The updated recommendations of the inter-
national ketogenic diet study group for the optimal clinical 
management of children receiving dietary therapies for epi-
lepsy8 provide an excellent guideline for initiation and man-
agement of KDT in Glut1DS (10/13, 77%). Issues specific to 
Glut1DS (survey question 8) are listed in Table 3. Key issues 
are the initiation of KDT as early as possible, essential blood 
ketone measurements targeting 2-5 mmol/L for blood beta-
hydroxybutyrate, and the continuation of KDT into adoles-
cence and adulthood. Supplements are essential in KDT, but 
recommendations for routine carnitine supplementation were 
controversial: Most centers check carnitine levels at regular 
intervals, while others supplement carnitine routinely (survey 
question 9,10).
Current data on antiseizure medication in Glut1DS are 
controversial and insufficient. The committee was concerned 
about the possibility of doing harm with the sole use of an-
tiseizure medications. Survey results showed that add-on 
antiseizure drugs in combination with KDT used in centers 
are levetiracetam (9/13, 69%) and valproic acid (9/13, 69%; 
not in girls beyond menarche), followed by lamotrigine (5/13, 
38%, survey question 6). Some centers considered ethosux-
imide, carbamazepine, oxcarbazepine, and zonisamide to be 
unhelpful. Currently, there is no basis to recommend any an-
tiseizure drug in the management of Glut1DS, and there are 
concerns regarding potential harmful interactions with KDT 
Paroxysmal events unresponsive to antiseizure medication 
have been treated with alpha-lipoic acid (2/13), triheptanoin 
(8/13), and acetazolamide (12/13) on an intention-to-treat 
basis (survey question 7). No recommendations can currently 
be made regarding effective PED treatment or the use of oral 
ketones or ketoesters.
3.4 | Glut1DS management and research
Follow-up. All patients with Glut1DS should be seen at regu-
lar intervals to monitor KDT, to address individual issues, 
and to share novel developments in the field.8,32,47 Follow-up 
needs to be age-specific as symptoms change from primar-
ily seizures in infancy-early childhood to movement disor-
ders such as dystonia and paroxysmal exertional dyskinesias 
in adolescence-adulthood.25 Cognitive dysfunction persists 
throughout life but there is no evidence for progressive wors-
ening.34 Long-term adverse effects of KDT such as growth 
impairment, nephrolithiasis, and cardiovascular risks need to 
be monitored at regular intervals.8
With patients approaching adulthood, it is critical to de-
velop a transitional plan for diet therapy and for medical care 
to transition from a pediatric to an adult subspecialist.41
Research. A family of hexose and MCT transporters pro-
vides metabolic fuel for the brain. At the cellular level, Glut1 
molecules function as tetramers86 to facilitate glucose transport 
across tissue barriers. The impact of Glut1DS on these sys-
tems is complex and the subject of ongoing research. SLC2A1 
variants could destabilize GLUT1 native interactions, gener-
ate novel interactions, trigger protein misfolding, and enhance 
protein aggregation.87 Glut1DS could be influenced by non-
coding RNA genes88,89 as well as downstream defects in Glut1 
translation, transcription, processing, activating, and traffick-
ing.90,91 Research into disease mechanisms has identified 
novel targets for therapy by focusing (a) on the link between 
the fundamental metabolic defect (ie, brain glucose depletion 
or neuroglycopenia) and its metabolic and neurophysiological 
consequences, (b) on the mechanisms of transporter dysfunc-
tion,79,92,93 and (c) on the MRI and PET-based investigation 
of human brain metabolism.94 These ongoing studies are en-
abling the development of supplemental metabolites to com-
pensate for the neuroglycopenia as therapeutic strategies.80 
Glut1 haploinsufficiency arrests brain angiogenesis during 
brain development, and the diminished brain capillary net-
work further aggravates neuroglycopenia.95 Approaches to re-
store Glut1 protein content and function include upregulation 
of the normal SLC2A1 allele using small molecule strategies 
or gene transfer strategies whereby a normal SLC2A1 gene is 
delivered in a suitable viral vector to the Glut1-deficient pa-
tient.82 Preclinical experiments in Glut1DS model mice using 
AAV9 vectors have demonstrated that gene replacement is ef-
fective and durable: Brain Glut1 expression and CSF glucose 
concentrations increase, brain growth and volume are main-
tained during development, motor performance is preserved, 
seizure activity is controlled, and brain angiogenesis proceeds 
normally.82,95,96 In contrast to successful presymptomatic or 
early symptomatic treatment, gene replacement in adult mice 
failed to improve symptoms, suggesting a therapeutic win-
dow of opportunity. This observation in Glut1DS and other 
neurodevelopmental disorders emphasizes the fundamental 
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importance of newborn screening for such genetically deter-
mined conditions to facilitate early postnatal diagnosis and 
proactive treatment before the onset of symptoms and irre-
versible damage to the developing brain.
Committee conclusions
There was general agreement that patients should be moni-
tored regularly for long-term side effects of KDT such as 
kidney stones, growth retardation, and cardiovascular disease 
(blood pressure, fasting lipid profiles, transcranial Doppler 
ultrasound from age 10  years). Long-term use of KDT in 
Glut1DS might generate adverse effects that might be more 
evident than shorter term use of KDT in drug-resistant child-
hood epilepsy. Discontinuing KDT, the current standard of 
care for Glut1DS, in favor of clinical trials that are designed 
to investigate novel treatment considerations was rejected 
strongly by the group (12/13, 92%).
4 |  DISCUSSION
The increasing complexity of Glut1DS, since its original 
description in 1991,2 has highlighted the need to develop 
an expert consensus based on questionnaires, international 
conferences, and round table discussions. Experts agreed 
that clinical signs suggestive of Glut1DS warrant a prompt 
diagnostic workup. A properly controlled diagnostic lumbar 
puncture plus SLC2A1 analysis remain critical to confirm 
Glut1DS. Normoglycemia, hypoglycorrhachia, and a low 
to normal CSF lactate concentration are necessary biomark-
ers for the diagnosis. KDT remain the standard of care and 
represent the best treatment for Glut1DS paroxysmal mani-
festations. The choice of KDT is influenced by several fac-
tors including patient age and tolerability.8 The importance 
of early diagnosis and treatment cannot be exaggerated. In 
classical cases of Glut1DS, the KDT should be started as 
early as possible postnatally with the highest degree of ke-
tosis maintained to mitigate brain energy deficiency by pro-
viding optimal concentrations of metabolic fuels (glucose 
and ketone bodies) to the developing brain. It is less clear 
whether this biological rule applies to the milder phenotypes 
but experience with other genetic diseases suggests that it 
does. Deceleration of head growth during early infancy is an 
ominous sign of irreversible brain dysfunction.
Controversies arose, as expected, because of the lack of 
data on unresolved issues regarding Glut1DS. Centers have 
had to develop individual protocols that remain to be modi-
fied on the base of this consensus and future research studies. 
Disagreements revolved around basic issues such as the nor-
mal range of CSF glucose concentrations, SLC2A1 variants of 
unclear significance, asymptomatic family members diagnosed 
with SLC2A1 variants, and the use of KDT in pregnant Glut1DS 
patients. Treatment decisions are less clear in atypical variants 
of Glut1DS, especially in oligosymptomatic or late-onset pa-
tients, because of limited experience. Newborn screening for 
this treatable disease is essential but remains to be established.
Despite the effectiveness of KDT, there is an unmet need 
in Glut1DS for additional therapies and novel approaches. 
Unresolved treatment issues involved the concomitant use of 
antiseizure drugs, compounds such as acetazolamide, canna-
bidiol, ketone salts, and ketone esters, and the pharmacolog-
ical treatment of paroxysmal events, dystonia, and dysarthria 
that significantly impair patients' quality of life. Transition 
to adult medicine is often difficult for patients and treating 
physicians. It remains unclear how long dietary treatment 
should be continued in the management of adult Glut1DS and 
how long-term adverse effects should be monitored and ad-
dressed.32,69 Future research also needs to address the impact 
of Glut1 deficiency on other organs rich in Glut1 transporters 
such as heart, muscle, placenta, and retina.97–100 The find-
ing of impaired cerebral angiogenesis during development in 
Glut1DS model mice emphasizes the importance of early di-
agnosis and proactive treatment to prevent irreversible brain 
damage. Future therapies for Glut1DS are focusing on sup-
plemental brain metabolic fuels, SLC2A1 transfer, and small 
molecules designed to enhance Glut1 expression or activity.82
This first consensus emphasized the phenotypic heteroge-
neity of Glut1DS and key issues surrounding diagnosis, treat-
ment, and long-term management. Discussions highlighted 
areas of consensus, topics of controversy, and future chal-
lenges. These management guidelines are primarily meant to 
be informative as it relates to the current state of the art. The 
consensus committee fully expects that these guidelines can be 
superseded when dictated by individual unique patient circum-
stances. The committee also recognized the ongoing demand 
for optimal clinical care of the aging Glut1DS patients and the 
continuing need to improve transitional care to optimize long-
term management and treatment throughout the life cycle.
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